drug
mivocabtagene autoleucel
Phase 3updated 3mo agoby $KYTX Kyverna Therapeutics, Inc.
Phase 3community read0 votes
all catalysts(0)
nothing on the calendar yet
News(3)
- Kyverna taps ElevateBio to secure commercial supply of autoimmune CAR-T therapyElevateBio will be the primary source of Kyverna’s autologous CAR-T cell therapy for anticipated U.S. and global launches in autoimmune indications.biospace · 16d ago
- Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapiesRoche may have scrapped work on a T-cell engager being evaluated for lupus, but the company’s head of pharma told Fierce that still has a strategy for developing cell therapies for autoimmune disea…fiercebiotech · 22d ago
- How Kyverna rode CAR T’s autoimmune wave to the FDA’s doorPoised to become the first company to achieve a regulatory filing for a cell therapy in autoimmune disease, Kyverna Therapeutics is building a pipeline-in-a-product to change the treatment paradigm.biospace · 25d ago
Data sources
last refreshed 48m ago
Found something off?
comments(0)
5-min edit window · permanent after that